人工智能驱动的囊性纤维化体积CT结局评分:伴或不伴调节剂治疗的纵向与多中心验证
回顾性验证研究纳入139例囊性纤维化患者,评估人工智能驱动的NOVAA-CT自动定量评分与肺功能及Bhalla评分的相关性,并在ETI和ABPA治疗组中纵向评估其反应性;NOVAA-CT与肺功能及Bhalla评分相关性显著,可重复性高,能定量显示ETI治疗后的气道异常体积可逆性。
要点
- NOVAA-CT自动量化支气管扩张、支气管周围增厚、支气管黏液、细支气管黏液、肺不张/实变及总异常体积。
- NOVAA-CT与肺功能及Bhalla评分在所有组均显著相关,标准化总异常体积ρ≥0.76(p<0.001)。
- ETI和ABPA治疗后支气管周围增厚、支气管黏液、细支气管黏液及肺不张/实变均显著改善(p≤0.001)。
核心结论
- NOVAA-CT自动评分在整体肺范围监测囊性纤维化严重程度方面具有有效性、可靠性和反应性,可定量评估ETI等治疗对肺结构的体积学效应。
研究设计与样本
- 回顾性验证研究,2010年至2023年,纳入139例囊性纤维化患者(中位年龄15岁,四分位距13-25岁),包括单中心ETI组60例、单中心ABPA组20例及6家地理上不同机构的多中心外部组59例,均完成CT和肺功能检查,ETI或ABPA治疗者在1年时进行第二次评估;以肺功能检查和视觉Bhalla评分为参照。
关键影像表现/征象
- NOVAA-CT可量化支气管扩张、支气管周围增厚、支气管黏液、细支气管黏液、肺不张/实变及其总体总异常体积(TAV)。
- 在ETI组、ABPA组和外部组中,NOVAA-CT与肺功能及Bhalla评分的所有相关性均显著,如标准化TAV的ρ≥0.76(p<0.001)。
诊断标准与关键数值
- NOVAA-CT自动测量气道异常的标准化体积(NOVAA-CT),包括支气管扩张、支气管周围增厚、支气管黏液、细支气管黏液、肺不张/实变及总异常体积(TAV)。
- 可重复性组内相关系数>0.99。
临床应用与阅片要点
- NOVAA-CT可作为客观、可重复、整体肺范围的囊性纤维化严重程度监测工具,并可作为治疗试验中的终点指标。
- ETI和ABPA组纵向显示支气管周围增厚、支气管黏液、细支气管黏液及肺不张/实变显著改善(p≤0.001);ETI组还量化出支气管扩张体积的额外可逆性(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Holistic segmentation of CT structural alterations with 3D deep learning has recently been described in cystic fibrosis (CF), allowing the measurement of normalized volumes of airway abnormalities (NOVAA-CT) as an automated quantitative outcome. Clinical validations are needed, including longitudinal and multicenter evaluations.
MATERIALS AND METHODS: The validation study was retrospective between 2010 and 2023. CF patients undergoing Elexacaftor/Tezacaftor/Ivacaftor (ETI) or corticosteroids for allergic broncho-pulmonary aspergillosis (ABPA) composed the monocenter ETI and ABPA groups, respectively. Patients from six geographically distinct institutions composed a multicenter external group. All patients had completed CT and pulmonary function test (PFT), with a second assessment at 1 year in case of ETI or ABPA treatment. NOVAA-CT quantified bronchiectasis, peribronchial thickening, bronchial mucus, bronchiolar mucus, collapse/consolidation, and their overall total abnormal volume (TAV). Two observers evaluated the visual Bhalla score.
RESULTS: A total of 139 CF patients (median age, 15 years [interquartile range: 13-25]) were evaluated. All correlations between NOVAA-CT to both PFT and Bhalla score were significant in the ETI (n = 60), ABPA (n = 20), and External groups (n = 59), such as the normalized TAV (ρ ≥ 0.76; p < 0.001). In both ETI and ABPA groups, there were significant longitudinal improvements in peribronchial thickening, bronchial mucus, bronchiolar mucus and collapse/consolidation (p ≤ 0.001). An additional reversibility in bronchiectasis volume was quantified with ETI (p < 0.001). Intraclass correlation coefficient of reproducibility was > 0.99.
CONCLUSION: NOVAA-CT automated scoring demonstrates validity, reliability and responsiveness for monitoring CF severity over an entire lung and quantifies therapeutic effects on lung structure at CT, such as the volumetric reversibility of airway abnormalities with ETI.
CLINICAL RELEVANCE STATEMENT: Normalized volume of airway abnormalities at CT automated 3D outcome enables objective, reproducible, and holistic monitoring of cystic fibrosis severity over an entire lung for management and endpoints during therapeutic trials.
KEY POINTS: Visual scoring methods lack sensitivity and reproducibility to assess longitudinal bronchial changes in cystic fibrosis (CF). AI-driven volumetric CT scoring correlates longitudinally to disease severity and reliably improves with Elexacaftor/Tezacaftor/Ivacaftor or corticosteroid treatments. AI-driven volumetric CT scoring enables reproducible monitoring of lung disease severity in CF and quantifies longitudinal structural therapeutic effects.
引用
- Hadj Bouzid AI, Bui S, Benlala I, et al. Artificial intelligence-driven volumetric CT outcome score in cystic fibrosis: longitudinal and multicenter validation with/without modulators treatment. Eur Radiol. 2024. PMID: 39150489. doi:10.1007/s00330-024-11019-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。